Skip to content

Prospective Evaluation of Patients With Pleural Effusion

Prospective Evaluation of the Aetiologies, Management and Clinical Outcomes in Patients With Pleural Effusion

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05759117
Enrollment
1000
Registered
2023-03-08
Start date
2022-09-01
Completion date
2026-03-31
Last updated
2023-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pleural Effusion

Brief summary

Having a pleural effusion is a common reason for being hospitalized, as it usually requires in-patient care for invasive diagnostic and therapeutic procedures. Specific subtypes of pleural effusion may warrant recurrent admissions, a longer hospital stay and consume more healthcare resources. Despite the recent advancement of pleural medicine, better research is increasingly desired to fill the gaps in establishing an early diagnosis and optimal management of pleural effusion from various causes. Local data on different aspects of pleural effusion is also lacking.

Detailed description

The aetiologies of pleural effusion range from cardio-respiratory diseases, malignancy, infection to systemic inflammatory conditions. However, data on the exact incidence of individual causes of pleural effusion is inadequate. Conflicting results on the aetiologies of pleural effusion were shown in several retrospective and prospective studies based in different geographical regions, which may be explained by the different epidemiology of common diseases in the corresponding areas and patients recruited. Despite a common clinical problem, the incidence and aetiology of pleural effusion have not been examined on a population level in Hong Kong. Therefore, a local study is necessary to inform physicians about the disease burden of pleural effusion. The management of pleural disease can be heterogeneous, as reflected by a recent multi-institutional questionnaire study in Hong Kong. Infrequent updates of international guidelines of pleural medicine, lack of an established registry reflecting the patient burden, procedure load and complications may contribute. Delayed or suboptimal management of pleural diseases can lead to unnecessary invasive procedures, prolonged hospital stays and even higher mortality rates. A local registry should be established to stocktake and understand diagnostic accuracy and complication rates of pleural procedures and reflects the real-life practice by hospital physicians. This prospective study aims at evaluating the aetiology and management of pleural diseases prospectively. The management by the attending doctors will not be interfered. Recruited patients will be divided into subgroups based on their characteristics for further analysis. The data collected from this study will guide the planning of subsequent research to overcome the knowledge and service gap in managing pleural diseases.

Interventions

PROCEDUREthoracentesis

A type of pleural procedure that will yield pleural fluid for subsequent analysis

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients hospitalized for pleural effusion. * Pleural tapping will be performed for pleural fluid analysis. * Aged 18 years old or above

Exclusion criteria

\- Failed to obtain informed consent due to the patient's refusal or cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
Aetiology of pleural effusion1 monthspectrum of aetiology for pleural effusion

Secondary

MeasureTime frameDescription
Management of pleural effusion1 monthcommon clinical practice of handling pleural effusion will be evaluated
Prognosis of pleural effusion1 monthneed for hospitalization, pleural procedure, complication rate and time required to establish a diagnosis for patients with pleural effusion will be evaluated

Countries

Hong Kong

Contacts

Primary ContactKa Pang Chan, MBChB
chankapang@cuhk.edu.hk35052211

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026